Compare PCVX & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | PLXS |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | United States |
| Employees | N/A | 20000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.0B |
| IPO Year | 2020 | 1995 |
| Metric | PCVX | PLXS |
|---|---|---|
| Price | $49.89 | $274.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $88.25 | ★ $206.50 |
| AVG Volume (30 Days) | ★ 1.6M | 284.9K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.11 |
| EPS | N/A | ★ 3.32 |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $14.31 |
| Revenue Next Year | N/A | $8.29 |
| P/E Ratio | ★ N/A | $79.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.10 | $115.83 |
| 52 Week High | $65.00 | $275.83 |
| Indicator | PCVX | PLXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 67.10 |
| Support Level | $42.30 | $133.69 |
| Resistance Level | $56.04 | $275.83 |
| Average True Range (ATR) | 2.47 | 7.95 |
| MACD | -0.51 | -1.19 |
| Stochastic Oscillator | 34.37 | 96.78 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.